

# Epimic Epidemiology Series: Acne Vulgaris Forecast in 19 Major Markets 2018–2028

<https://marketpublishers.com/r/E576DE96B07EN.html>

Date: June 2018

Pages: 84

Price: US\$ 5,800.00 (Single User License)

ID: E576DE96B07EN

## Abstracts

Black Swan Analysis Epimic Epidemiology Series Forecast Report on Acne Vulgaris in 19 Major Markets

Acne, or Acne Vulgaris (AV), is a chronic inflammatory disease of the pilosebaceous unit. Although acne can develop at any age, it most commonly affects adolescents and is triggered by the overproduction of sebum in the sebaceous glands. Acne vulgaris is characterised by presence of comedones, papules, pustules, cysts, nodules and, occasionally, scars. It can affect the face, anterior chest and upper back.

This report provides the current prevalent population for Acne Vulgaris across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, main classes of the disease by severity, type and grade, as well as disease aetiology, manifestations and co-morbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Acne Vulgaris include:

Underlying hormone imbalance

Puberty

Family history

Skin scarring

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

## **REASON TO BUY**

Able to quantify patient populations in global Acne Vulgaris market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of Acne Vulgaris and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on Acne Vulgaris prevalent population.

Identify sub-populations within Acne Vulgaris which require treatment.

Gain an understanding of the specific markets that have the largest number of Acne Vulgaris patients.

## Contents

INTRODUCTION  
CAUSE OF THE DISEASE  
RISK FACTORS & PREVENTION  
DIAGNOSIS OF THE DISEASE  
VARIATION BY GEOGRAPHY/ETHNICITY  
DISEASE PROGNOSIS & CLINICAL COURSE  
KEY COMORBID CONDITIONS/FEATURES ASSOCIATED WITH THE DISEASE  
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS  
TOP-LINE PREVALENCE FOR ACNE VULGARIS  
FEATURES OF ACNE VULGARIS PATIENTS  
CLASSIFICATION  
SEVERITY  
SIGNS  
LESION LOCATION  
OTHER FEATURES  
COMORBIDITIES OF ACNE VULGARIS PATIENTS  
ABBREVIATIONS USED IN THE REPORT  
OTHER BLACK SWAN SERVICES & SOLUTIONS  
REPORTS & PUBLICATIONS  
ONLINE EPIDEMIOLOGY DATABASES  
ONLINE PHARMACEUTICAL PRICING DATABASE  
REFERENCES  
APPENDIX

## List Of Tables

### LIST OF TABLES AND FIGURES

- Table 1. Grading of acne vulgaris
- Table 2. Prevalence of acne vulgaris, total (000s)
- Table 3. Prevalence of acne vulgaris, males (000s)
- Table 4. Prevalence of acne vulgaris, females (000s)
- Table 5. Patients with acne vulgaris by type, total (000s)
- Table 6. Patients with inflammatory acne vulgaris by subtype, total (000s)
- Table 7. Patients with acne vulgaris by severity, total (000s)
- Table 8. Patients with acne vulgaris by severity grade, total (000s)
- Table 9. Acne vulgaris patients with nodules, total (000s)
- Table 10. Acne vulgaris patients with comedones, total (000s)
- Table 11. Acne vulgaris patients with pustules, total (000s)
- Table 12. Patients with acne vulgaris by severity of skin oiliness, total (000s)
- Table 13. Acne vulgaris patients with scarring, total (000s)
- Table 14. Acne vulgaris patients with ice pick scarring, total (000s)
- Table 15. Acne vulgaris patients with hypertrophy scarring, total (000s)
- Table 16. Acne vulgaris patients with atrophy scarring, total (000s)
- Table 17. Acne vulgaris patients with lesions on the cheeks, total (000s)
- Table 18. Acne vulgaris patients with lesions on the forehead, total (000s)
- Table 19. Acne vulgaris patients with lesions on the mandible, total (000s)
- Table 20. Acne vulgaris patients with lesions on the chin, total (000s)
- Table 21. Acne vulgaris patients with lesions on the nose, total (000s)
- Table 22. Acne vulgaris patients with lesions on the neck, total (000s)
- Table 23. Acne vulgaris patients with lesions on the back, total (000s)
- Table 24. Acne vulgaris patients with lesions on the chest, total (000s)
- Table 25. Acne vulgaris patients with lesions on other body parts, total (000s)
- Table 26. Acne vulgaris patients with physiological acne, total (000s)
- Table 27. Acne vulgaris patients with premenstrual flare, females (000s)
- Table 28. Acne vulgaris patients with hyperplasia, total (000s)
- Table 29. Acne vulgaris patients with hyperplasia by type, total (000s)
- Table 30. Patients with acne vulgaris by propionibacterial resistance, total (000s)
- Table 31. Acne vulgaris patients with a family history of the disease, total (000s)
- Table 32. Acne vulgaris patients with depression, total (000s)
- Table 33. Acne vulgaris patients with polycystic ovary syndrome, females (000s)
- Table 34. Abbreviations and acronyms used in the report
- Table 35. USA prevalence of acne vulgaris by 5-yr age cohort, males (000s)

- Table 36. USA prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 37. Canada prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 38. Canada prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 39. France prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 40. France prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 41. Germany prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 42. Germany prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 43. Italy prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 44. Italy prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 45. Spain prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 46. Spain prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 47. UK prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 48. UK prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 49. Poland prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 50. Poland prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 51. Netherlands prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 52. Netherlands prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 53. Russia prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 54. Russia prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 55. Turkey prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 56. Turkey prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 57. Japan prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 58. Japan prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 59. China prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 60. China prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 61. South Korea prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 62. South Korea prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 63. India prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 64. India prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 65. Australia prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 66. Australia prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 67. Brazil prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 68. Brazil prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 69. Mexico prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 70. Mexico prevalence of acne vulgaris by 5-yr age cohort, females (000s)  
Table 71. Argentina prevalence of acne vulgaris by 5-yr age cohort, males (000s)  
Table 72. Argentina prevalence of acne vulgaris by 5-yr age cohort, females (000s)

## I would like to order

Product name: Epiomic Epidemiology Series: Acne Vulgaris Forecast in 19 Major Markets 2018–2028

Product link: <https://marketpublishers.com/r/E576DE96B07EN.html>

Price: US\$ 5,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E576DE96B07EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970